| Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations TF Eleveld, DA Oldridge, V Bernard, J Koster, LC Daage, SJ Diskin, ... Nature genetics 47 (8), 864-871, 2015 | 593 | 2015 |
| Revised neuroblastoma risk classification system: a report from the Children's Oncology Group MS Irwin, A Naranjo, FF Zhang, SL Cohn, WB London, JM Gastier-Foster, ... Journal of Clinical Oncology 39 (29), 3229-3241, 2021 | 324 | 2021 |
| Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial JR Park, SG Kreissman, WB London, A Naranjo, SL Cohn, MD Hogarty, ... Jama 322 (8), 746-755, 2019 | 309 | 2019 |
| Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial R Mody, A Naranjo, C Van Ryn, LY Alice, WB London, BL Shulkin, ... The lancet oncology 18 (7), 946-957, 2017 | 273 | 2017 |
| A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study JG Nuchtern, WB London, CE Barnewolt, A Naranjo, PW McGrady, ... Annals of surgery 256 (4), 573-580, 2012 | 224 | 2012 |
| Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group GA Yanik, MT Parisi, BL Shulkin, A Naranjo, SG Kreissman, WB London, ... Journal of nuclear medicine 54 (4), 541-548, 2013 | 218 | 2013 |
| Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study J Vermeulen, K De Preter, A Naranjo, L Vercruysse, N Van Roy, ... The lancet oncology 10 (7), 663-671, 2009 | 200 | 2009 |
| Children's Oncology Group's 2013 blueprint for research: renal tumors JS Dome, CV Fernandez, EA Mullen, JA Kalapurakal, JI Geller, V Huff, ... Pediatric blood & cancer 60 (6), 994-1000, 2013 | 189 | 2013 |
| Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032 AL Yu, AL Gilman, MF Ozkaynak, A Naranjo, MB Diccianni, J Gan, ... Clinical Cancer Research 27 (8), 2179-2189, 2021 | 168 | 2021 |
| Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group R Mody, AL Yu, A Naranjo, FF Zhang, WB London, BL Shulkin, MT Parisi, ... Journal of Clinical Oncology 38 (19), 2160-2169, 2020 | 163 | 2020 |
| Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study JR Park, JR Scott, CF Stewart, WB London, A Naranjo, VM Santana, ... Journal of clinical oncology 29 (33), 4351-4357, 2011 | 154 | 2011 |
| Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group … WB London, R Bagatell, BJ Weigel, E Fox, D Guo, C Van Ryn, A Naranjo, ... Cancer 123 (24), 4914-4923, 2017 | 152 | 2017 |
| High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk EV Barnes, S Narain, A Naranjo, J Shuster, MS Segal, ES Sobel, ... Lupus 14 (8), 576-582, 2005 | 152 | 2005 |
| Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study LL Wang, R Teshiba, N Ikegaki, XX Tang, A Naranjo, WB London, ... British journal of cancer 113 (1), 57-63, 2015 | 149 | 2015 |
| Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group K Campbell, JM Gastier‐Foster, M Mann, AH Naranjo, C Van Ryn, ... Cancer 123 (21), 4224-4235, 2017 | 143 | 2017 |
| Pan-neuroblastoma analysis reveals age-and signature-associated driver alterations SW Brady, Y Liu, X Ma, AM Gout, K Hagiwara, X Zhou, J Wang, M Macias, ... Nature communications 11 (1), 5183, 2020 | 136 | 2020 |
| Characterization of adolescent and pediatric renal cell carcinoma: a report from the Children's Oncology Group study AREN03B2 JI Geller, PF Ehrlich, NG Cost, G Khanna, EA Mullen, EJ Gratias, ... Cancer 121 (14), 2457-2464, 2015 | 119 | 2015 |
| MYCN amplification and ATRX mutations are incompatible in neuroblastoma M Zeineldin, S Federico, X Chen, Y Fan, B Xu, E Stewart, X Zhou, J Jeon, ... Nature communications 11 (1), 913, 2020 | 118 | 2020 |
| Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG C Okamatsu, WB London, A Naranjo, MD Hogarty, JM Gastier‐Foster, ... Pediatric blood & cancer 53 (4), 563-569, 2009 | 118 | 2009 |
| miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples K De Preter, P Mestdagh, J Vermeulen, F Zeka, A Naranjo, I Bray, ... Clinical Cancer Research 17 (24), 7684-7692, 2011 | 106 | 2011 |
John M MarisProfessor Pediatrics, Children's Hospital of Philadelphia and University of PennsylvaniaΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα chop.edu
